A Multi-Centre Double-Blind Randomised Placebo-Controlled Trial Of Oral Anticoagulation In Systemic Sclerosis-Related Pulmonary Arterial Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$1,190,521.00
Summary
Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improve ....Scleroderma is an autoimmune disease that shortens life span by over 30 years. The main cause of death is pulmonary arterial hypertension (PAH), a condition of increased pressure in the lung vessels. Even in the era of 'advanced' PAH therapy, only 50% of patients are alive beyond 5 years. Formation of clots in the small blood vessels of the lung plays a major role in the development of PAH. In this clinical trial we aim to determine whether anticoagulation (treatment to prevent clotting) improves survival in scleroderma PAH.Read moreRead less